926 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
GILD Gilead Sciences, Inc. $72.78 $94.35B Uptrend
Article Searches
The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy http://www.zacks.com/stock/news/417959/the-zacks-analyst-blog-highlights-disney-coca-cola-gilead-cme-and-entergy?cid=CS-ZC-FT-417959 May 22, 2019 - The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy
Top Stock Reports for Disney, Coca-Cola & Gilead http://www.zacks.com/research-daily/417448/top-stock-reports-for-disney-coca-cola-gilead?cid=CS-ZC-FT-417448 May 21, 2019 - Top Stock Reports for Disney, Coca-Cola & Gilead
GILD, NVO, ZYNE and NOG among notable after hour movers https://seekingalpha.com/news/3465165-gild-nvo-zyne-nog-among-notable-hour-movers?source=feed_news_all May 17, 2019 - Top Gainers: GILD +3.1%. NOG +3.2%. NBRV +2.7%. GOL +2.3%. NIO +1%.Top Losers: LTM -4.7%. SIGA -1.9%. NKTR -1.8%. NVO -1.7%. ZYNE -1.7%.
Mallinckrodt Ends Enrollment in Phase III for Terlipressin http://www.zacks.com/stock/news/414520/mallinckrodt-ends-enrollment-in-phase-iii-for-terlipressin?cid=CS-ZC-FT-414520 May 15, 2019 - Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates http://www.zacks.com/stock/news/414511/biotech-stock-roundup-fda-nod-for-regns-eylea-in-dr-tie-ups-other-updates?cid=CS-ZC-FT-414511 May 15, 2019 - Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.
GILD vs. ILMN: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/413278/gild-vs-ilmn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-413278 May 13, 2019 - GILD vs. ILMN: Which Stock Is the Better Value Option?
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss http://www.zacks.com/stock/news/412852/agenus-agen-q1-earnings-beat-estimates-revenues-miss?cid=CS-ZC-FT-412852 May 10, 2019 - Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates http://www.zacks.com/stock/news/412270/horizon-therapeutics-hznp-q1-earnings-beat-estimates?cid=CS-ZC-FT-412270 May 09, 2019 - Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/412101/intercept-icpt-q1-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-412101 May 09, 2019 - Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
5 Things You Can Expect for Gilead Sciences With Its New CEO at the Helm https://www.fool.com/investing/2019/05/05/5-things-you-can-expect-for-gilead-sciences-with-a.aspx?source=iedfolrf0000001 May 05, 2019 - Gilead's new CEO, Dan O'Day, gives several hints about where the big biotech is headed in his comments in the Q1 earnings conference call.

Pages: 123456...93

Page 1>